Assessment of Human Pancreas Cancer Tissue and Precursor Lesions via a Fluorophore With Inherent PDAC Selectivity
The current five-year survival rate of in vivoand ex vivo in a murine model. In the current study, human PDAC tissue is targeted. Compound 1 selectively stains ducts of the adenocarcinoma versus the surrounding stroma, enabling the imaging of PDAC in frozen tissue sections with high contrast. To enhance the potential of 1 for intraoperative applications, the ex vivo staining protocol was optimized for rapid margin assessment, with a final staining time of ~15 min. To measure diagnostic performance, the area under a receiver operating characteristic (ROC) curve was measured for the identification of ductal adenocarcinoma vs. stroma. The bright fluorescence contrast enabled quantitative determination of PDAC (or precancerous PanIN lesions) versus healthy pancreas tissue in human tissue array samples.
Locate the Document
Munhenzva, I. R., Barth, C. W., Sibrian-Vazquez, M., Wang, L. G., Escobedo, J. O., Gibbs, S. L., & Strongin, R. M. (2019). Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity. Methods (San Diego, Calif.).